Imunopharm Technology

Immunochina, founded in 2015 in Beijing, is a clinical-stage biopharmaceutical company with the slogan "Make the incurable curable". The company is dedicated to developing innovative cell and gene therapies to combat serious diseases such as cancer and autoimmune disorders. It boasts an integrated autonomous platform for research and industrialization in the biotechnology and pharmaceutical industries. Immunochina's pipeline includes treatments for hematologic malignancies like lymphoma, leukemia, multiple myeloma, and solid tumors such as liver cancer and colorectal cancer. The company has presented clinical data of its CAR-T products at renowned international conferences including ASCO, ASH, IMS, and ESMO. Particularly noteworthy is its in-house CAR-T therapy product, IM96, which has shown groundbreaking efficacy and safety data in early clinical trials targeting GUCY2C for the treatment of late-stage metastatic colorectal cancer. The company has successfully completed 9 rounds of strategic financing and secured the CAR-T drug production license with 5 China INDs. The most recent injection of funds came from China Taiping Insurance in a Venture Round investment on 08 May 2023. Immunochina has solidified its position as a cornerstone in CAR-T therapy in China, making significant strides in the development of potential FIC therapies for late-stage CRC.